What is claimed is:

1. Use of a pharmaceutical composition in the manufacture of a medicament for treating chemotherapy-induced diarrhea (CID) in a human subject undergoing chemotherapy and in need thereof, the composition comprising an effective amount of crofelemer to treat CID.

2. The use of claim 1, wherein the crofelemer is to be administered in combination with the chemotherapy.

3. The use of claim 1, wherein the crofelemer is to be administered at the same time as the chemotherapy to reduce or delay the onset of CID.

4. The use of claim 1, wherein the crofelemer is to be administered before chemotherapy.

5. The use of claim 1, wherein the crofelemer is to be administered after chemotherapy.

6. The use of any previous claim, wherein the chemotherapy is selected from alkylating agents, anthracyclines, cytoskeletal disruptors (taxanes), epothilones, histone deacetylase inhibitors, inhibitors of topoisomerase I, inhibitors of topoisomerase II, kinase inhibitors, nucleotide analogs and precursor analogs, peptide antibiotics, platinum-based agents and retinoids.

7. The use of claim 6, wherein the chemotherapy comprises one or more tyrosine kinase inhibitors.

8. The use of claim 7, wherein the tyrosine kinase inhibitor is selected from lapatinib, sunitinib, sorafenib, erlotinib, gefitinib, axitinib, imatinib, nilotinib, dasatinib, cabozantinib, ruxolitinib, neratinib, bosutinib, pazopanib, afatninib, lenvatinib, tucatinib, vandetanib, ceritinib, crizotinib, dacomitinib, and valatinib.

9. The use of claim 7, wherein the tyrosine kinase inhibitor (TKI) is selected from anaplastic lymphoma kinase (ALK) TKI (e.g., crizotinib, ceritinib and alectinib).

10. The use of claim 6, wherein the chemotherapy is a phosphoinositide 3-kinase inhibitor.

11. The use of claim 10, wherein the phosphoinositide 3-kinase inhibitor is alpelisib.

12. The use of claim 6, wherein the chemotherapy is a CDK (cyclin-dependent kinase) 4/6/ inhibitor, optionally, abemaciclib.

13. The use of any one of claims 1 to 6, wherein the chemotherapy comprises one or more HER (Human epidermal growth factor receptor) inhibitors.

14. The use of claim 9, wherein the HER (Human epidermal growth factor receptor) inhibitor is selected from RG7116, RG1273 (pertuzumab, Perjeta®), RG3502 (trastuzumab emantasine, T-DMI), RG597 (trastuzumab, HERCEPTIN), RGA201 (RG7160), erlotinib (Tarceva®), dacomitinib (PF-00299804), PF-05280014 (Pfizer's biosimilar mAB to RG597).

15. The use of claim 1, wherein the crofelemer is to be administered for the duration of treatment with the chemotherapy.

16. The use of claim 1, wherein the composition comprises an amount suitable for administration of 250 mg two times per day or administration of about 500 mg two times per day.

17. The use of claim 1, wherein the crofelemer is to be administered as an enteric coated oral dosage form.

18. The use of claim 1, wherein the subject can tolerate the chemotherapy that the subject could not tolerate without the administration of crofelemer or can tolerate a higher dosage of chemotherapy than the subject could tolerate without administration of crofelemer.

19. The use of claim 1, wherein a subject is considered treated if the subject demonstrates one or more of a decrease in the number of bowel movements per day, a decrease in the number of watery bowel movements per day, an improvement in the daily abdominal score for pain or discomfort, an improvement in the score for daily stool consistency, a decrease in stool consistency, a decrease in the number of days per week that subjects experienced urgency, a decrease in the number of days per week that subjects experienced fecal incontinence, or a decrease in the unscheduled visit for a significant worsening of diarrhea.

20. The use of claim 1, wherein the administration results in a decrease in 1, 2 or 3 Grades of the Grade of diarrhea according to the Common Toxicity Criteria.

21. The use of claim 1, wherein the subject is undergoing chemotherapy to treat a cancer selected from breast cancer, ovarian cancer, prostate cancer, bladder cancer, cervical cancer, uterine cancer, testicular cancer, kidney cancer, thyroid cancer, oral or oropharyngeal cancer, astrocytoma, sarcoma, mesothelioma, meningioma, lymphoma, myeloma, head and neck cancer, lung cancer, carcinoma (e.g., squamous cell carcinoma), malignant melanoma, peritoneal cancer,

gastric cancer, hepatic cancer, colorectal cancer, gallbladder cancer, bone cancer, pancreatic cancer, tongue cancer, esophageal cancer, brain tumor, brain stem glioma, a metastases thereof, and leukemia.

22. Use of a composition in the manufacture of a medicament for treating CID in a human subject undergoing chemotherapy for HER positive breast cancer, wherein the composition comprises crofelemer at a dose of 125 mg twice per day, wherein the chemotherapy is trastuzumab, pertuzumab, docetaxel, paclitaxel, or neratinib, or a combination thereof, with or without carboplatin.